Mr. Bulllock, CEO of Harvard Stem Cell Research Institute, is the Chief Investment Officer of Stem Cell and Regenerative Medicine of Guosheng Investment and Medici Medical Group.
On May 8, 2015, Hong Kong Medici Medical Group and Guosheng Investment (01227.HK) announced the appointment of Mr. Brock Rif as the chief stem cell and regenerative medicine investment officer of the two companies.
Mr. Bulllock is currently the Executive Director of the Harvard University Stem Cell Institute and has graduated from Yale University and Harvard Business School. Mr. Reeve is solely responsible for the strategy and operations of the Harvard Stem Cell Institute, whose overall goal is to use stem cell biology as a tool and treatment to study and treat major degenerative diseases.
As the Chief Investor of Stem Cell and Regenerative Medicine of Medici Medical Investment Group, Mr. Bulllock will organize and lead a professional investment team to actively select the latest regenerative medicine technologies in overseas markets such as Europe, the United States, and Japan and evaluate their investment value. Focus on and invest in the world's leading stem cell regenerative medicine technology, and actively participate in clinical trials and product commercialization of stem cell technology invested by McGrady Medical Group in Asia.
Medici Medical Group is the world's most authoritative investment organization in stem cell and regenerative medicine
As the world's most authoritative investment organization for stem cells and regenerative medicine, Medici Medical Group has invested in stem cell treatment technologies including heart, tumor, liver, kidney, AIDS and other diseases, fully demonstrating its investment vision and courage. After working with the Mayo Medical Group in the United States, he once again joined forces with the Harvard University Stem Cell Institute.
Mr. Wang Xiaofeng is the Chairman of the Medici Medical Group and Chairman of Guosheng Investment (01227.HK). He has devoted himself to research and investment in the field of stem cells for the past five years. The Group currently has more than 300 scientists and medical consultants from all over the world. And investment experts, the technology invested in Europe, the United States, Japan, Hong Kong and other places, and simultaneously carry out clinical trials.
China's first participation in international multi-center global synchronized clinical trials
The McGrady Medical Group is committed to bringing the world's leading stem cell and regenerative medicine technologies to China. The investment in the C-cure Stem Cell Therapy for Ischemic Heart Failure has been clinically tested in Europe and the United States. With the support of international multi-center policy, clinical trials will be conducted in China's well-known cardiovascular hospitals such as Beijing Anzhen Hospital, Fuwai Cardiovascular Hospital and Shanghai Oriental Hospital, giving Chinese hospitals the opportunity to participate in the world's most advanced stem cell technology clinic. Experiment and actively promote the commercialization of technology worldwide in the future. Before C-Cure's great technology and revolutionary products for heart disease were officially launched, McGrady has launched a series of cell regeneration factor products to treat a number of diseases, and the product has entered the market.
Liang Zhenying visits Harvard University Stem Cell Research Institute and Mr. Brock Reeve to discuss the promotion of stem cell and regenerative medicine industry
Under the general environment of Hong Kong's adjustment of the whole industry, one of the important measures is to develop the stem cell and regenerative medicine industries. Looking at the huge investment in the stem cell and regeneration field of the McGrady Medical Group, it is revealed that it will inevitably set off a disruptive business model in the market.
The Hong Kong government attaches great importance to the development of stem cells. Following the cooperation with the Caroline Medical School in Sweden, the Chief Executive Liang Zhenying visited the Harvard University Stem Cell Research Institute on May 5 and exchanged views with its Executive Director Brock Reeve to promote the development of the stem cell industry in Hong Kong. This will undoubtedly inject a strong shot into the cooperation between Harvard University and Hong Kong in the field of regenerative medicine. It will promote the promotion of Harvard stem cells in regenerative medicine research and technology in Hong Kong and Asia.
It can be seen that McGrady Medical Group has appointed Mr. Brock Rif to take the helm of the stem cell and regenerative medicine at the helm of the group. Guosheng Investment (01227.HK), which holds a 30% stake in Medici Medical Group, is investing in regenerative medicine. Committed to the investment strategy and direction in the field of stem cells, Mr. Reeve will lead the McGrady Medical Group's professional stem cell investment team with global leadership.
The prospects for the stem cell and regenerative medicine industry under the capital markets of China and Hong Kong are immeasurable
With the upcoming clinical management of stem cells, the development of China's stem cell and regenerative medicine industry will be unstoppable. Shanghai-Hong Kong Stock Connect and the upcoming Shenzhen-Hong Kong Stock Connect have apparently injected huge sums of money into Hong Kong stocks. The stocks of companies related to the stem cell industry have risen very well, but they are far from satisfactory and far from the technology held by Medivh Medical. Guosheng Investment (01227.HK), as a shareholder of Medici Medical Group, is full of confidence in the development of the Group.
Medici Investment Holdings' Cardio Biotech plans to enter the US capital market
McGrady Investment Holdings' C-cure Stem Cell Therapy for Ischemic Heart Failure has exceeded the number of patients enrolled by the European Food and Drug Administration (EMA) in the Phase III clinical trial in Europe and has been approved by the US Food and Drug Administration (FDA). Enter the third phase of clinical. Cadillac, the investment holding company of McGrady, also successfully obtained a new round of financing of 32 million euros in February this year. Its financing quota was oversubscribed and snapped up by European and American institutional investors. Cardio is planning to be in the end of May to early June this year. The US Nasdaq is listed on the third place (listed in Belgium and France in 2013), and the large-scale financing plan of Cardio further indicates that the spring of stem cells has really come.
After many years of favor and investment in the field of stem cells and regenerative medicine, and the huge capital investment plan, the next step will be the focus of the market. The expectation of the capital market for the future development of McGrady has been fully demonstrated. The confidence of the shareholder Guosheng Investment (01227.HK). According to analysts, McGrady has planned to launch an overall listing financing plan in Hong Kong in the near future. We believe that McGrady, as a recognized leader in the global stem cell and regenerative medicine field, will surely launch an incredible wave of development in this field. 
Mr. Brockerf is the friend of Medivh Medical Group and Chairman of Guosheng Investment Fund (01227.HK), Mr. Wang Xiaofeng, who lives in the United States and has a common confidence and enthusiasm for the development of stem cell and regenerative medicine industry.
　　
Hong Kong Chief Executive Leung Chun-ying visited the Harvard University Stem Cell Institute and exchanged views with the Executive Director, Mr. Brock Reeve, on the development of the stem cell and regenerative medicine industries.
Brockeriff is the younger brother of the famous American actor Christopher Reeve.
Christopher Reeve (September 25, 1952 - October 10, 2004), a New York City, New York City, famous film actor, film director, writer, plays Superman / Card in the movie "Superman" - Al/Clark Kent is famous. He graduated from Cornell University in 1974 with a Bachelor of Arts degree and then entered the Juilliard School in New York. He is also a good friend with another famous actor Robin Williams. In 1978, he starred in the sci-fi film "Superman" for the first time, "Superman", and became a hit. In 1995, an accident occurred during an equestrian competition. The spine was seriously injured and his body was paralyzed. Since then, he has devoted himself to social welfare undertakings, is committed to promoting stem cell research, and often holds tour lectures. On October 9, 2004, the myocardial infarction fell into a coma and died the next day at the age of 52.
　　
　　
Torque Hinges,Constant Torque Hinge,Adjustable Torque Hinge,Torque Door Hinges
Ningbo Hengchieh Locking Technology Co., Ltd. , https://www.hengchieh.com